
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences is a Buy with a promising outlook driven by its well-rounded portfolio of transcatheter and surgical heart valve products, including the successful TAVR business which has stabilized and has potential for re-acceleration with the asymptomatic rollout and possible NCD update. The company's upcoming product launches in mitral and tricuspid therapies and its focus on margin expansion also support a positive long-term growth trajectory. Other potential catalysts, such as the final TAVR NCD and new product approvals, add to the company's potential for success in the dynamic macroeconomic environment. With a solid growth profile, competitive moat, and best-in-class product pipeline, Edwards Lifesciences is well-suited to outperform in the cardiovascular device market.
Bears say
Edwards Lifesciences is an established leader in the medical device industry, with a strong focus on advanced stages of structural heart disease. While the company has recently outperformed its peers, its current premium valuation may not be sustainable given potential market saturation and competitive pressures. The company's large percentage of international sales also exposes it to currency and geopolitical risks. Additionally, increased investments and expenses related to its field salesforce and patient access initiatives may weigh on profitability in the short term.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares